Search

Bexarotene

Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.

Demeclocycline

Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.

Telisotuzumab vedotin

to be approved for this specific patient population. … [L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment

Cladribine

[A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell … [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718]

RPI-78M

RPI-78M is being developed for the treatment of multiple sclerosis (MS).

Dengue tetravalent vaccine, live

Fluoroestradiol F-18

across metastases (i.e. to identify sites that no longer express ER) without the need for multiple biopsies. … [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression

Apalutamide

In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo [L1295]. … Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer.

Vimseltinib

[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate … [L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase.

Ethambutol

[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.